| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloid-Lymphoid Leukemia Protein | 25 | 2024 | 77 | 2.600 |
Why?
|
| Leukemia, Myeloid, Acute | 22 | 2025 | 826 | 2.090 |
Why?
|
| Histone-Lysine N-Methyltransferase | 22 | 2024 | 166 | 1.390 |
Why?
|
| Oncogene Proteins, Fusion | 10 | 2022 | 134 | 1.330 |
Why?
|
| Leukemia | 9 | 2017 | 301 | 1.320 |
Why?
|
| DNA-Binding Proteins | 22 | 2019 | 1234 | 1.140 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 9 | 2025 | 98 | 1.070 |
Why?
|
| Proto-Oncogenes | 14 | 2005 | 60 | 1.060 |
Why?
|
| Azacitidine | 10 | 2025 | 149 | 1.060 |
Why?
|
| Neoplasm Proteins | 9 | 2013 | 537 | 1.020 |
Why?
|
| Translocation, Genetic | 18 | 2016 | 248 | 1.010 |
Why?
|
| Peptide Elongation Factors | 7 | 2005 | 27 | 0.990 |
Why?
|
| Transcription Factors | 20 | 2013 | 1691 | 0.960 |
Why?
|
| Sulfonamides | 9 | 2025 | 331 | 0.950 |
Why?
|
| Leukemia, Myeloid | 11 | 2012 | 240 | 0.940 |
Why?
|
| Cell Transformation, Neoplastic | 7 | 2017 | 457 | 0.820 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2025 | 666 | 0.780 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2025 | 2544 | 0.760 |
Why?
|
| Gene Expression Regulation, Leukemic | 4 | 2011 | 99 | 0.710 |
Why?
|
| Chromosomes, Human, Pair 11 | 16 | 2003 | 106 | 0.560 |
Why?
|
| Antigens, CD34 | 2 | 2016 | 161 | 0.550 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2019 | 147 | 0.500 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 65 | 0.470 |
Why?
|
| Anemia | 2 | 2020 | 134 | 0.460 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2024 | 423 | 0.430 |
Why?
|
| Homeodomain Proteins | 3 | 2013 | 556 | 0.390 |
Why?
|
| Transcriptional Elongation Factors | 10 | 2009 | 24 | 0.380 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2013 | 295 | 0.340 |
Why?
|
| Humans | 76 | 2025 | 93515 | 0.320 |
Why?
|
| Mitoxantrone | 3 | 2020 | 65 | 0.310 |
Why?
|
| Mice | 21 | 2017 | 12269 | 0.300 |
Why?
|
| Nuclear Proteins | 4 | 2025 | 740 | 0.290 |
Why?
|
| Hematopoietic Stem Cells | 5 | 2019 | 319 | 0.290 |
Why?
|
| Aged | 26 | 2025 | 20434 | 0.270 |
Why?
|
| Acute Disease | 10 | 2013 | 841 | 0.260 |
Why?
|
| Gene Rearrangement | 8 | 2024 | 168 | 0.260 |
Why?
|
| Remission Induction | 9 | 2023 | 738 | 0.250 |
Why?
|
| Myelodysplastic Syndromes | 6 | 2013 | 379 | 0.250 |
Why?
|
| Myeloproliferative Disorders | 3 | 2024 | 146 | 0.250 |
Why?
|
| Mutation | 9 | 2025 | 4272 | 0.250 |
Why?
|
| Aging | 1 | 2011 | 727 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 2 | 2018 | 10 | 0.230 |
Why?
|
| Cell Lineage | 2 | 2017 | 321 | 0.230 |
Why?
|
| Animals | 24 | 2017 | 28155 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 6 | 2013 | 42 | 0.220 |
Why?
|
| Aged, 80 and over | 11 | 2025 | 7061 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2013 | 1338 | 0.210 |
Why?
|
| Lymphoma, T-Cell | 3 | 2013 | 61 | 0.210 |
Why?
|
| CD47 Antigen | 1 | 2024 | 24 | 0.210 |
Why?
|
| Coiled Bodies | 1 | 2003 | 2 | 0.200 |
Why?
|
| Transplantation Conditioning | 4 | 2013 | 383 | 0.200 |
Why?
|
| Neutropenia | 1 | 2024 | 209 | 0.200 |
Why?
|
| Male | 35 | 2025 | 44557 | 0.200 |
Why?
|
| Transcriptional Activation | 3 | 2019 | 290 | 0.190 |
Why?
|
| Thrombocytopenia | 2 | 2020 | 189 | 0.190 |
Why?
|
| Cytarabine | 3 | 2020 | 216 | 0.190 |
Why?
|
| Dancing | 1 | 2022 | 1 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2024 | 636 | 0.190 |
Why?
|
| Female | 33 | 2025 | 48702 | 0.180 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 2303 | 0.180 |
Why?
|
| Prognosis | 8 | 2025 | 3911 | 0.180 |
Why?
|
| Lymphoma | 4 | 2012 | 247 | 0.180 |
Why?
|
| Consolidation Chemotherapy | 2 | 2018 | 23 | 0.180 |
Why?
|
| Middle Aged | 23 | 2025 | 27573 | 0.170 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 624 | 0.170 |
Why?
|
| Janus Kinase 2 | 2 | 2019 | 59 | 0.170 |
Why?
|
| Febrile Neutropenia | 1 | 2020 | 16 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 19 | 3 | 2003 | 61 | 0.160 |
Why?
|
| Benzamides | 4 | 2025 | 246 | 0.160 |
Why?
|
| Molecular Sequence Data | 9 | 2002 | 2910 | 0.160 |
Why?
|
| Amino Acid Sequence | 7 | 2002 | 2012 | 0.160 |
Why?
|
| Spiro Compounds | 3 | 2025 | 22 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 7 | 2011 | 1028 | 0.160 |
Why?
|
| MicroRNAs | 3 | 2010 | 580 | 0.160 |
Why?
|
| Protein Binding | 5 | 2023 | 1534 | 0.150 |
Why?
|
| Aminopyridines | 1 | 2020 | 48 | 0.150 |
Why?
|
| Triazines | 1 | 2020 | 54 | 0.150 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2020 | 61 | 0.150 |
Why?
|
| Lymphoma, B-Cell | 2 | 2013 | 107 | 0.150 |
Why?
|
| Cloning, Molecular | 5 | 1997 | 587 | 0.150 |
Why?
|
| Recurrence | 5 | 2025 | 1190 | 0.150 |
Why?
|
| Retroviridae | 5 | 2013 | 73 | 0.150 |
Why?
|
| Treatment Outcome | 10 | 2025 | 9099 | 0.150 |
Why?
|
| Adult | 23 | 2025 | 27918 | 0.150 |
Why?
|
| Neoplasms, Second Primary | 3 | 2012 | 245 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 603 | 0.150 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2010 | 201 | 0.140 |
Why?
|
| Indazoles | 1 | 2019 | 58 | 0.140 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2018 | 48 | 0.140 |
Why?
|
| Chromosome Deletion | 2 | 2016 | 214 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2020 | 876 | 0.140 |
Why?
|
| Pyrazines | 1 | 2019 | 93 | 0.140 |
Why?
|
| Quercetin | 1 | 2018 | 3 | 0.140 |
Why?
|
| Transfection | 4 | 2007 | 880 | 0.140 |
Why?
|
| Hematopoiesis | 1 | 2019 | 183 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2017 | 244 | 0.140 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 4 | 2023 | 132 | 0.130 |
Why?
|
| Cell Compartmentation | 1 | 1997 | 69 | 0.130 |
Why?
|
| Zinc Fingers | 6 | 2010 | 58 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2016 | 109 | 0.120 |
Why?
|
| HeLa Cells | 4 | 2010 | 517 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2017 | 939 | 0.120 |
Why?
|
| Pneumonia | 2 | 2020 | 193 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2010 | 555 | 0.120 |
Why?
|
| Pyrimidines | 2 | 2016 | 384 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2016 | 150 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 6 | 3 | 2007 | 127 | 0.110 |
Why?
|
| Chromosome Aberrations | 5 | 2012 | 350 | 0.110 |
Why?
|
| Bone Marrow Transplantation | 2 | 1996 | 281 | 0.110 |
Why?
|
| Repressor Proteins | 2 | 2013 | 443 | 0.110 |
Why?
|
| Patient Safety | 1 | 2018 | 218 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2017 | 454 | 0.110 |
Why?
|
| Cytokines | 1 | 2019 | 863 | 0.110 |
Why?
|
| RNA Polymerase II | 2 | 2009 | 60 | 0.110 |
Why?
|
| Benzo(a)pyrene | 1 | 1994 | 6 | 0.110 |
Why?
|
| Arteriosclerosis | 1 | 1994 | 106 | 0.100 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1994 | 77 | 0.100 |
Why?
|
| RNA, Messenger | 9 | 2013 | 2026 | 0.100 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2013 | 20 | 0.100 |
Why?
|
| Oncogene Proteins v-myb | 1 | 2013 | 3 | 0.100 |
Why?
|
| Transplantation, Homologous | 5 | 2017 | 1014 | 0.100 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 61 | 0.100 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 37 | 0.100 |
Why?
|
| Aorta | 1 | 1994 | 273 | 0.100 |
Why?
|
| Adolescent | 12 | 2024 | 9606 | 0.100 |
Why?
|
| Cell Line, Tumor | 4 | 2012 | 2755 | 0.090 |
Why?
|
| Apoptosis | 4 | 2010 | 1721 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2018 | 761 | 0.090 |
Why?
|
| Cell Line | 7 | 2009 | 2464 | 0.090 |
Why?
|
| Bronchiolitis Obliterans | 1 | 1992 | 37 | 0.090 |
Why?
|
| Superoxide Dismutase | 1 | 2012 | 155 | 0.090 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2011 | 24 | 0.090 |
Why?
|
| Blotting, Northern | 3 | 2002 | 244 | 0.080 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2011 | 22 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2011 | 46 | 0.080 |
Why?
|
| Neoplasm, Residual | 2 | 2023 | 196 | 0.080 |
Why?
|
| Stem Cell Transplantation | 3 | 2012 | 192 | 0.080 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2008 | 175 | 0.080 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 3 | 1996 | 15 | 0.080 |
Why?
|
| Erythropoietin | 1 | 2011 | 90 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2012 | 205 | 0.080 |
Why?
|
| Hemoglobins | 1 | 2011 | 191 | 0.080 |
Why?
|
| Sequence Alignment | 2 | 2001 | 352 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 7 | 1996 | 361 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 3830 | 0.080 |
Why?
|
| Survival Rate | 3 | 2025 | 1948 | 0.080 |
Why?
|
| Epigenomics | 1 | 2011 | 109 | 0.080 |
Why?
|
| Methylation | 1 | 2011 | 288 | 0.080 |
Why?
|
| Immunohistochemistry | 5 | 2018 | 1799 | 0.080 |
Why?
|
| Caspase 3 | 1 | 2010 | 162 | 0.080 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 329 | 0.080 |
Why?
|
| Young Adult | 5 | 2024 | 6930 | 0.080 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2009 | 15 | 0.080 |
Why?
|
| Genetic Loci | 1 | 2011 | 260 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2013 | 4560 | 0.080 |
Why?
|
| Conserved Sequence | 2 | 2002 | 209 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2495 | 0.080 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2009 | 16 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 3 | 2009 | 894 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 392 | 0.070 |
Why?
|
| Histones | 1 | 2011 | 361 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2011 | 730 | 0.070 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1723 | 0.070 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 1170 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2011 | 375 | 0.070 |
Why?
|
| Blood Component Removal | 1 | 2008 | 28 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2011 | 960 | 0.070 |
Why?
|
| Age Factors | 2 | 2025 | 1906 | 0.070 |
Why?
|
| Gene Expression Profiling | 3 | 2009 | 1518 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2009 | 287 | 0.070 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2008 | 110 | 0.070 |
Why?
|
| Melphalan | 2 | 2005 | 98 | 0.070 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 158 | 0.070 |
Why?
|
| Vidarabine | 2 | 2005 | 93 | 0.070 |
Why?
|
| Base Sequence | 7 | 2008 | 2220 | 0.060 |
Why?
|
| Hematologic Neoplasms | 1 | 2011 | 372 | 0.060 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2007 | 2 | 0.060 |
Why?
|
| Prevalence | 1 | 2011 | 1321 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2007 | 22 | 0.060 |
Why?
|
| Chromosome Inversion | 1 | 2007 | 45 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2009 | 697 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 829 | 0.060 |
Why?
|
| Bone Marrow | 3 | 2008 | 409 | 0.060 |
Why?
|
| Karnofsky Performance Status | 1 | 2006 | 43 | 0.060 |
Why?
|
| Myosin Heavy Chains | 1 | 2007 | 86 | 0.060 |
Why?
|
| Precision Medicine | 1 | 2011 | 456 | 0.060 |
Why?
|
| Chromatin | 2 | 2022 | 440 | 0.060 |
Why?
|
| Immune Complex Diseases | 1 | 2006 | 19 | 0.060 |
Why?
|
| Karyotyping | 4 | 2011 | 222 | 0.060 |
Why?
|
| Complement Factor H | 1 | 2006 | 34 | 0.060 |
Why?
|
| Genetic Vectors | 2 | 2013 | 422 | 0.060 |
Why?
|
| Transcription, Genetic | 5 | 2009 | 1117 | 0.060 |
Why?
|
| Meperidine | 1 | 1985 | 11 | 0.060 |
Why?
|
| Complement System Proteins | 1 | 2006 | 86 | 0.060 |
Why?
|
| Blood Platelets | 1 | 2006 | 150 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2008 | 988 | 0.060 |
Why?
|
| Dioxygenases | 2 | 2019 | 82 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1997 | 404 | 0.060 |
Why?
|
| Inflammation | 1 | 2011 | 1050 | 0.060 |
Why?
|
| Kidney | 2 | 2010 | 1111 | 0.060 |
Why?
|
| DNA, Neoplasm | 6 | 1996 | 266 | 0.060 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2005 | 11 | 0.060 |
Why?
|
| Emergencies | 1 | 1985 | 122 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 5 | 2009 | 962 | 0.050 |
Why?
|
| Bone Marrow Cells | 1 | 2006 | 264 | 0.050 |
Why?
|
| Binding Sites | 3 | 2002 | 1133 | 0.050 |
Why?
|
| Chromosome Mapping | 7 | 1996 | 1052 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2011 | 3054 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2024 | 165 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 148 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 1985 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2004 | 134 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2018 | 1524 | 0.050 |
Why?
|
| snRNP Core Proteins | 1 | 2003 | 9 | 0.050 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2003 | 20 | 0.050 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 555 | 0.050 |
Why?
|
| Immunosorbent Techniques | 1 | 2002 | 11 | 0.050 |
Why?
|
| Sequence Homology | 1 | 2002 | 26 | 0.050 |
Why?
|
| Genes | 2 | 1994 | 258 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2024 | 10164 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1448 | 0.050 |
Why?
|
| Seizures | 1 | 1985 | 311 | 0.050 |
Why?
|
| Aspartic Acid | 1 | 2002 | 66 | 0.050 |
Why?
|
| Genes, Regulator | 1 | 2022 | 59 | 0.050 |
Why?
|
| Mice, Transgenic | 3 | 2013 | 1587 | 0.050 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2003 | 65 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 108 | 0.050 |
Why?
|
| Serine | 1 | 2002 | 105 | 0.050 |
Why?
|
| Glutamic Acid | 1 | 2002 | 147 | 0.050 |
Why?
|
| Autoantigens | 1 | 2003 | 138 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2003 | 259 | 0.040 |
Why?
|
| Biomarkers | 2 | 2019 | 1910 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2018 | 657 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 2001 | 108 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 1914 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2002 | 470 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 920 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2006 | 2850 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 80 | 0.040 |
Why?
|
| Leukopenia | 1 | 2020 | 64 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2002 | 524 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2002 | 603 | 0.040 |
Why?
|
| Core Binding Factors | 2 | 2011 | 12 | 0.040 |
Why?
|
| Gene Transfer Techniques | 1 | 2000 | 154 | 0.040 |
Why?
|
| Ethylnitrosourea | 2 | 2012 | 30 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 990 | 0.040 |
Why?
|
| In Situ Hybridization | 2 | 1997 | 309 | 0.040 |
Why?
|
| RNA | 1 | 2003 | 573 | 0.040 |
Why?
|
| Comorbidity | 2 | 2017 | 1007 | 0.040 |
Why?
|
| Retreatment | 1 | 2019 | 104 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2018 | 34 | 0.040 |
Why?
|
| Hematologic Diseases | 2 | 2012 | 77 | 0.040 |
Why?
|
| Cell Survival | 2 | 2012 | 1004 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2004 | 1120 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2018 | 91 | 0.030 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2019 | 103 | 0.030 |
Why?
|
| Tretinoin | 1 | 2018 | 129 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2000 | 439 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 146 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2002 | 893 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 96 | 0.030 |
Why?
|
| Topoisomerase II Inhibitors | 2 | 1996 | 27 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2018 | 217 | 0.030 |
Why?
|
| Cell Self Renewal | 1 | 2017 | 23 | 0.030 |
Why?
|
| Cellular Microenvironment | 1 | 2017 | 31 | 0.030 |
Why?
|
| DNA Primers | 3 | 2008 | 531 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2018 | 131 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 401 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 2441 | 0.030 |
Why?
|
| Embryonic and Fetal Development | 1 | 1997 | 68 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1997 | 68 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 259 | 0.030 |
Why?
|
| Graft vs Host Disease | 2 | 2005 | 365 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 402 | 0.030 |
Why?
|
| RNA, Small Interfering | 2 | 2010 | 555 | 0.030 |
Why?
|
| Child, Preschool | 5 | 1996 | 3829 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 1997 | 217 | 0.030 |
Why?
|
| Proteins | 1 | 2002 | 803 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 1133 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2020 | 1729 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 188 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 108 | 0.030 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 1996 | 22 | 0.030 |
Why?
|
| Adenine | 1 | 2016 | 90 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 358 | 0.030 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1995 | 9 | 0.030 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1995 | 5 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 1775 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1995 | 80 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1995 | 47 | 0.030 |
Why?
|
| Piperidines | 1 | 2016 | 165 | 0.030 |
Why?
|
| RNA, Neoplasm | 3 | 2007 | 86 | 0.030 |
Why?
|
| Species Specificity | 1 | 1997 | 684 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 917 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 887 | 0.030 |
Why?
|
| Gene Library | 1 | 1994 | 126 | 0.030 |
Why?
|
| Methylcholanthrene | 1 | 1994 | 10 | 0.030 |
Why?
|
| Microsomes | 1 | 1994 | 32 | 0.030 |
Why?
|
| Biotransformation | 1 | 1994 | 46 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 1994 | 83 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1994 | 80 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1994 | 102 | 0.030 |
Why?
|
| Gene Deletion | 1 | 1995 | 352 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 690 | 0.030 |
Why?
|
| Radiotherapy | 1 | 1996 | 320 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1994 | 113 | 0.030 |
Why?
|
| Organ Specificity | 1 | 1994 | 279 | 0.030 |
Why?
|
| Fetus | 1 | 1994 | 236 | 0.020 |
Why?
|
| X Chromosome | 1 | 1994 | 154 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2006 | 889 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1103 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 2017 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1993 | 63 | 0.020 |
Why?
|
| GTPase-Activating Proteins | 1 | 2013 | 68 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1994 | 302 | 0.020 |
Why?
|
| Alkylating Agents | 1 | 2012 | 32 | 0.020 |
Why?
|
| Genetic Markers | 1 | 1993 | 469 | 0.020 |
Why?
|
| Mercaptoethylamines | 1 | 2012 | 52 | 0.020 |
Why?
|
| Child | 5 | 1996 | 7355 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2012 | 193 | 0.020 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 1992 | 24 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2012 | 3435 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2012 | 88 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2013 | 3502 | 0.020 |
Why?
|
| Gene Expression | 3 | 2004 | 1301 | 0.020 |
Why?
|
| Liver | 1 | 1997 | 1210 | 0.020 |
Why?
|
| Prednisone | 1 | 1992 | 242 | 0.020 |
Why?
|
| Syndrome | 1 | 1992 | 437 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2012 | 103 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 1245 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1993 | 260 | 0.020 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2011 | 37 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 179 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2011 | 80 | 0.020 |
Why?
|
| Genes, ras | 1 | 2011 | 97 | 0.020 |
Why?
|
| Chromosome Banding | 3 | 1995 | 66 | 0.020 |
Why?
|
| United States | 1 | 2024 | 7622 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 409 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 657 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2010 | 32 | 0.020 |
Why?
|
| K562 Cells | 1 | 2010 | 48 | 0.020 |
Why?
|
| Chromosome Disorders | 3 | 1995 | 98 | 0.020 |
Why?
|
| Smoking | 1 | 1994 | 648 | 0.020 |
Why?
|
| Mitogens | 1 | 2009 | 59 | 0.020 |
Why?
|
| Consensus Sequence | 2 | 2002 | 65 | 0.020 |
Why?
|
| Multigene Family | 1 | 2010 | 203 | 0.020 |
Why?
|
| Restriction Mapping | 3 | 1993 | 120 | 0.020 |
Why?
|
| Cyclophilins | 1 | 2008 | 8 | 0.020 |
Why?
|
| Histone Deacetylase 1 | 1 | 2008 | 16 | 0.020 |
Why?
|
| Infant | 4 | 1996 | 3220 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2009 | 184 | 0.020 |
Why?
|
| Filgrastim | 1 | 2008 | 56 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2008 | 71 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2008 | 52 | 0.020 |
Why?
|
| Rats | 1 | 1994 | 4072 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 127 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 86 | 0.020 |
Why?
|
| Peptide Mapping | 1 | 2007 | 25 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2007 | 60 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2008 | 359 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2007 | 177 | 0.020 |
Why?
|
| Piperazines | 1 | 2008 | 284 | 0.020 |
Why?
|
| Myoclonus | 1 | 1985 | 13 | 0.010 |
Why?
|
| Hamartoma | 1 | 1985 | 33 | 0.010 |
Why?
|
| Pregnancy | 1 | 2012 | 3147 | 0.010 |
Why?
|
| Alemtuzumab | 1 | 2005 | 90 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 2005 | 85 | 0.010 |
Why?
|
| DNA, Complementary | 2 | 1996 | 384 | 0.010 |
Why?
|
| COS Cells | 1 | 2005 | 164 | 0.010 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2004 | 7 | 0.010 |
Why?
|
| Oncogenes | 1 | 2004 | 100 | 0.010 |
Why?
|
| Brain | 1 | 1994 | 2391 | 0.010 |
Why?
|
| DNA Probes | 2 | 1993 | 67 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2004 | 522 | 0.010 |
Why?
|
| Herpes Simplex Virus Protein Vmw65 | 1 | 2002 | 5 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2002 | 126 | 0.010 |
Why?
|
| Luciferases | 1 | 2002 | 129 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 1762 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 293 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2002 | 275 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2006 | 2121 | 0.010 |
Why?
|
| Rabbits | 1 | 2002 | 618 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 1741 | 0.010 |
Why?
|
| CREB-Binding Protein | 1 | 2000 | 16 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 1985 | 546 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 1101 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2005 | 1001 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 1395 | 0.010 |
Why?
|
| Neoplasms | 1 | 1993 | 3169 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2002 | 701 | 0.010 |
Why?
|
| Teniposide | 1 | 1996 | 6 | 0.010 |
Why?
|
| Centromere | 1 | 1996 | 27 | 0.010 |
Why?
|
| Risk Factors | 1 | 2006 | 5899 | 0.010 |
Why?
|
| Etoposide | 1 | 1996 | 204 | 0.010 |
Why?
|
| Telomere | 1 | 1996 | 120 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1994 | 46 | 0.010 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 1994 | 34 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1996 | 270 | 0.010 |
Why?
|
| Codon | 1 | 1994 | 116 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1994 | 129 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 1995 | 219 | 0.010 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 1993 | 8 | 0.010 |
Why?
|
| Leukemia, Lymphoid | 1 | 1993 | 48 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1993 | 68 | 0.010 |
Why?
|
| Introns | 1 | 1994 | 300 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1993 | 110 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1993 | 135 | 0.010 |
Why?
|
| RNA Splicing | 1 | 1994 | 157 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1992 | 948 | 0.010 |
Why?
|
| Drosophila | 1 | 1995 | 539 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1995 | 2479 | 0.000 |
Why?
|